NASDAQ:OCUL Ocular Therapeutix Q2 2026 Earnings Report $10.49 -0.13 (-1.22%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$10.69 +0.20 (+1.90%) As of 09/11/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ocular Therapeutix EPS ResultsActual EPS-$0.35Consensus EPS -$0.40Beat/MissBeat by +$0.05One Year Ago EPS-$0.39Ocular Therapeutix Revenue ResultsActual Revenue$13.48 millionExpected Revenue$13.20 millionBeat/MissBeat by +$274.00 thousandYoY Revenue Growth-0.10%Ocular Therapeutix Announcement DetailsQuarterQ2 2026Date8/3/2026TimeBefore Market OpensConference Call DateMonday, August 3, 2026Conference Call Time7:00AM ETUpcoming EarningsOcular Therapeutix's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ocular Therapeutix Earnings HeadlinesOcular Therapeutix (OCUL): Faster Path To Approval Comes With Rising CostsSeptember 3, 2026 | insidermonkey.comOcular Therapeutix™ to Participate in September and October Investor and Scientific ConferencesSeptember 1, 2026 | globenewswire.comChina's decline is now official. Here's the trade.The Financial Times just confirmed what one analyst has been saying for months: China's economy peaked in 2021, with real growth trending closer to zero than the official 5 percent figure. A record $425 billion in capital has already fled Chinese markets, with a third of remaining growth tied to AI exports now facing new political headwinds. History shows capital doesn't vanish when a major economy stumbles, it relocates. Kelly Maguire of Behind the Markets has identified where it may be heading next.September 12 at 1:00 AM | Behind the Markets (Ad)Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline UpdateAugust 22, 2026 | finance.yahoo.comOcular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI ProgressAugust 22, 2026 | finance.yahoo.comPharmaceuticals stocks Q2 highlights: Ocular Therapeutix (NASDAQ:OCUL)August 21, 2026 | msn.comSee More Ocular Therapeutix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email. Email Address About Ocular TherapeutixOcular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based technology to design sustained-release treatments intended to deliver medication to ocular tissues over extended periods and potentially reduce the need for frequent eye drops or injections. Its commercial product, Dextenza, is a resorbable intracanalicular insert that delivers dexamethasone to the ocular surface for the treatment of inflammation and pain following ophthalmic surgery. Dextenza is inserted into the tear duct by an eye-care professional and is designed to provide medication for up to 30 days. The company’s development pipeline includes AXPAXLI, an extended-release intravitreal implant containing axitinib that is being studied for retinal diseases, including wet age-related macular degeneration. Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts. The company’s products and clinical programs are primarily directed at the U.S. ophthalmology market, while its research and development activities support potential international expansion. Ocular Therapeutix is led by President and Chief Executive Officer Pravin U. Dugel, an ophthalmologist and industry executive with experience in retinal disease and ophthalmic drug development.View Ocular Therapeutix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
